The China CPAP market is projected to reach USD 596.4 million in the year 2025 and is expected to total USD 1,048.1 million by the end of 2035, growing at a compound annual growth rate (CAGR) of 5.8% over the forecast years from 2025 to 2035.
| Attributes | Values |
|---|---|
| Estimated China Industry Size 2025 | USD 596.4 million |
| Projected China Value 2035 | USD 1,048.1 million |
| Value-based CAGR from 2025 to 2035 | 5.8% |
The rapid economic growth in the country contributes to a higher rate of obesity, which is among the major leading causes of sleep disorder increases, thus pushing the demand for CPAP therapy higher. The local and international players dominate this competition landscape.
Even though the market offers platform for cost-effective local manufacturers making their way forward by giving the necessary solution to the Chinese consumers, it is actually filled with global majors such as ResMed, Philips Respironics, and Fisher & Paykel Healthcare.
There have also been government actions aimed at streamlining healthcare, and more patients become more inclined toward the adoption of home healthcare products. The CPAP market in China is also supplemented by the increased adoption of improving reimbursement policies within the Chinese Government toward medical devices such as CPAP treatment.
Besides hospital and sleep clinics being the mainstream platforms for diagnostics and prescription devices, the uptrend of healthcare and telemedicine will expand markets, thus promoting greater access towards CPAP.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The table below offers a detailed comparative assessment of the changes in the compound annual growth rate (CAGR) over six months for the base year (2023) and the current year (2024) specifically for the China Continuous Positive Airway Pressure Devices market.
This semiannual analysis highlights all the critical shifts of market dynamics as well as details the revenue realization pattern, thus more precisely providing to the stakeholders insight into the trajectory of growth within a year. In other words, H1 contains January to June, and the other half H2 contains July to December.
H1 signifies period from January to June, H2 Signifies period from July to December
China market is expected to grow in the CPAP sector at a CAGR of 6.1% in H1 of 2023, and by second half, it should be greater than 6.4%. This is expected to decline a bit at 5.8% in H1 of 2024. The same, however, should be up by H2 to 6.5%. This would represent a decrease of 26 basis points from the first half of 2023 to the first half of 2024 and was higher by 17 basis points in the second half of 2024 compared to the second half of 2023.
These figures represent a dynamic and fast-changing China Continuous Positive Airway Pressure Devices market, largely influenced by regulations, consumer trends, and improvements in Continuous Positive Airway Pressure Devices. This semestral breakup is crucial to businesses that chart their strategies, taking into consideration the growth trends and navigating market complexities.
| Date | Development/M&A Activity & Details |
|---|---|
| 2025 | Collaboration: SS TECHNOMED cooperates with research institutions and universities for innovation and technological development. |
| 2024 | Investment: Medtronics is investing in R&D for new products for the various segments of the health industry. It also focuses on bringing complementary products and services that create ancillary streams of revenue. |
| 2024 | Regulatory Standards: Fisher & Paykel Maintaining rigorous quality control processes to ensure that all products meet high standards of safety and reliability. This involves continuous monitoring and improvement of manufacturing processes. |
Incidence of sleep apnea and respiratory conditions is rising
Major demand drivers in the country are an increasingly high incidence of sleep apnea and other respiratory diseases, driven mainly by a growing population aging and obesity rates. The higher the diagnosed number of such diseases, the more rapidly is the demand for efficient therapeutic solutions, like CPAP devices.
Government Healthcare Initiatives and Reimbursement Policies
Moving forward, the Chinese government's initiatives to ensure healthcare accessible and at an affordable price would support access to CPAP therapy, with extended coverage of health insurance, reimbursement policies for health care products such as medical devices and others. These support the greater good and continue to play a pivotal role in driving market growth by reducing the financial burden for patients seeking treatment.
% share of Individual categories by Product Type and End User in 2025
PAP therapy now includes such main treatments, namely CPAP, BiPAP, and APAP therapy. Factors stimulating the demand include a growing problem with sleep disorder diagnoses, rates of obesity climbing through the sky, and exponentially rising knowledge base in undiagnosed instances of sleep apnea.
Favorable insurance coverage and reimbursement policies now exist for PAP treatments, thereby making therapy available to greater numbers of patients, as well as both patients and healthcare providers themselves.
Hospitals are the most important institutions in promoting the use of PAP devices since they are the primary institutions for diagnosing and managing respiratory conditions. Many patients are introduced to CPAP or BiPAP after undergoing sleep studies in hospital-based sleep centers.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The China CPAP market is evolving, with the competitive landscape of local and international players. The industry is growing steadily because of the increasing awareness of sleep disorders, the growing population of the aged, and the increased rates of obesity that have led to higher incidences of sleep apnea.
The factors are thus driving demand for CPAP devices because the need for effective treatment solutions continues to grow. The market is relatively fragmented, with key global brands such as ResMed, Philips Respironics, and Fisher & Paykel Healthcare maintaining strong footholds in China due to their advanced technology and established reputations.
These international companies often lead in terms of product innovation, offering features such as quieter machines, automatic pressure adjustments, and connectivity for remote monitoring, which are in high demand among patients and healthcare providers.
Simultaneously, local manufacturers are gaining market share by offering cost-effective alternatives that cater specifically to the needs of Chinese consumers-for example, inexpensive, compact, or travel-friendly CPAP devices. Local players also benefit from a deeper understanding of regional market dynamics and regulatory requirements.
2025 Market share of China Continuous Positive Airway Pressure Devices suppliers
Note: above chart is indicative in nature
In terms of product, the industry is divided into PAP Devices (CPAP, BIPAP, and Auto CPAP), Humidifier, Masks (Full Face Masks, Nasal Masks, and Nasal Pillow Masks) and Accessories.
In terms of patient type, the industry is segregated into infants, premature, adults.
In terms of indication, the industry is segregated into chronic respiratory failure, respiratory distress syndrome (RDS), sleep apnea disorders, hypoxemia and hypoxia, among other indications.
In terms of end user, the industry is divided into hospitals, home care settings, clinics, intensive care units and sleep disorder centers.
By 2025, the China Continuous Positive Airway Pressure Devices market is expected to grow at a CAGR of 5.8%.
By 2035, the sales value of the China Continuous Positive Airway Pressure Devices industry is expected to reach China is 1,048.1 million.
The key drivers fueling the growth of the China Continuous Positive Airway Pressure Devices market include the increasing incidence of chronic respiratory disorders and the growing obesity rates.
Prominent players in the China Continuous Positive Airway Pressure Devices manufacturing include ResMed, Fisher & Paykel Healthcare, Draegerwerk AG & Co. KGaA, Medtronics, ReactHealth (3B Medical, Inc.), DeVilbiss Healthcare, Armstrong Medical, BMC Medical Co. Ltd, Hamilton Medical AG, Hebei Topson Medical Technology Co., Ltd., Nanjing Superstar Medical Equipment, SS TECHNOMED, Inspiration Healthcare(Viomedex Limited), Pigeon Medical and Others. These companies are noted for their innovation, extensive product portfolios, and strategic market positioning.
Explore Therapeutic Device Insights
View Reports
China Continuous Positive Airway Pressure Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
